Core Viewpoint - The business cooperation between Beijing Beiyi Pharmaceutical and Peking University International Hospital is nearing completion, leading to potential risks of business cessation, personnel layoffs, and corporate transformation for Beiyi Pharmaceutical [1][2]. Group 1: Business Overview - Beijing Beiyi Pharmaceutical, a wholly-owned subsidiary of Beida Pharmaceutical, is primarily engaged in the distribution, retail, hospital procurement, and pharmacy management of third-party drugs, medical devices, and consumables [1]. - The contract between Beiyi Pharmaceutical and Peking University International Hospital, which was effective from May 2022 to May 2023, has expired, and both parties will not continue their cooperation, significantly impacting the revenue of both companies [2][4]. Group 2: Financial Impact - The loss of Peking University International Hospital as a client could lead to a significant revenue decline for Beiyi Pharmaceutical, with an estimated sales revenue reduction of approximately 600 million yuan, accounting for about 29.13% of the company's latest audited revenue [5]. - Beiyi Pharmaceutical's total revenue for 2024 is projected to be 2.06 billion yuan, with around 50% of this revenue dependent on the contract with the hospital [4][5]. - If the cooperation is completely terminated, Beiyi Pharmaceutical's profitability could shrink by nearly half, with a potential revenue decrease of about 1.027 billion yuan starting in 2026 [5]. Group 3: Market Reaction - On August 12, the stock price of Beida Pharmaceutical fell by over 9%, closing at 6.42 yuan per share, a decline of 7.36%, with a total market capitalization of 3.826 billion yuan [1]. Group 4: Industry Context - The situation reflects a typical case of over-reliance on a single major client, which can lead to severe financial consequences when the partnership ends [6]. - The healthcare industry is experiencing rapid changes, including accelerated medical reforms and centralized procurement, which may further compress traditional distribution margins [6].

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交7848.40万元，其中，买入成交额为 3971.77万元，卖出成交额为3876.63万元，合计净买入95.13万元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买一、买二、买三、买五、卖一、卖 二、卖四，合计买入金额3385.01万元，卖出金额2631.64万元，合计净买入753.37万元。 资金流向方面，今日该股主力资金净流出3527.48万元，其中，特大单净流出1611.16万元，大单资金净 流出1916.31万元。近5日主力资金净流出6597.05万元。（数据宝） 北大医药今日下跌7.36%，全天换手率11.13%，成交额4.26亿元，振幅6.71%。龙虎榜数据显示，机构净 买入753.37万元，营业部席位合计净卖出658.23万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-7.69%上榜，机构专用席位净买入753.37万元。 北大医药8月12日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 1225 ...

(本文来自第一财经) 北大医药今日跌7.36%，龙虎榜数据显示，4机构合计买入3385.01万元，卖出2631.64万元，合计净买入 753.37万元。 ...

Core Viewpoint - The termination of the business cooperation between Beijing Beida Pharmaceutical's subsidiary and Peking University International Hospital poses significant risks to the company's main operations, potentially leading to a substantial loss in revenue and profit due to its heavy reliance on this partnership [1][2][3]. Group 1: Business Impact - The termination of cooperation with the International Hospital has resulted in a projected revenue decrease of approximately 6 billion yuan for the current year, which accounts for about 29.13% of the company's most recent audited revenue [2]. - The company anticipates a net profit reduction of around 40 million yuan, representing about 28.99% of the latest audited net profit attributable to shareholders [2]. - Starting in 2026, the company may face even greater losses, with projected revenue declines of 10.27 billion yuan and net profit reductions of approximately 68.69 million yuan, which could account for nearly 50% of the company's recent audited revenue and net profit [2]. Group 2: Business Transition - In response to the loss of its primary client, the company is shifting its focus towards pharmaceutical manufacturing, establishing a new subsidiary based on its production center to enhance its capabilities in generic drug production [1][3]. - The pharmaceutical distribution business, which heavily relied on the International Hospital, generated 14.37 billion yuan in revenue in 2024, making up 69.75% of the company's total revenue [3]. - The company has announced plans to concentrate resources on the manufacturing segment to improve efficiency and leverage its strengths in generic drug production [3][4]. Group 3: Financial Performance - In 2024, the company's pharmaceutical manufacturing revenue was 6.23 billion yuan, accounting for approximately 30% of total revenue, with a gross margin of 57.47%, significantly higher than the 13.48% gross margin from the pharmaceutical distribution business [4]. - The company's generic drug products have been affected by centralized procurement policies, which have led to a decline in gross margin by 11.23 percentage points compared to the previous year [5].

Core Viewpoint - The termination of the exclusive cooperation between Peking University Medicine's core subsidiary and Peking University International Hospital is expected to significantly impact the company's revenue, leading to a projected decrease of 1 billion yuan in revenue for the next year, causing a 7% drop in stock price [2][3]. Revenue Impact - The long-term service contract with the International Hospital, which was the sole provider of medical equipment, surgical instruments, and pharmaceuticals, contributed 814 million yuan in revenue in 2022, accounting for 39.19% of the company's total revenue [3]. - The projected revenue from the International Hospital for 2023 and 2024 is 986 million yuan and 1.123 billion yuan, respectively, representing 44.94% and 54.51% of total revenue [3]. - The termination is expected to reduce sales revenue by 600 million yuan in the second half of the year and net profit by 40 million yuan, with a total revenue decrease of 1.027 billion yuan and net profit decrease of 68.69 million yuan in 2026 [4]. Financial Performance - In 2024, the company is projected to achieve total revenue of 2.06 billion yuan, a decrease of 6.10% from 2023, while net profit is expected to be 138 million yuan, a 211% increase year-on-year [5]. - The pharmaceutical distribution business is expected to contribute 1.437 billion yuan, accounting for 69.75% of total revenue in 2024 [6]. Transformation Challenges - The termination of the cooperation poses a significant challenge to the company's business structure and future development strategy, as it has historically relied heavily on this partnership [6]. - The company has undergone multiple transformations, shifting from raw material production to formulation and medical services since 2015, and has increased R&D investment in key areas [7]. - In 2024, R&D investment is expected to reach 40.13 million yuan, a 12.22% increase year-on-year, indicating the company's efforts to diversify and innovate [7].

格隆汇8月12日｜北大医药(000788.SZ)大幅下跌一度逼近跌停，现报6.31元，总市值37.7亿元。消息上，因为失去了一家医院的业务，北大医药全资子公司 面临关停风险，自身业绩也将因此受累。 8月11日晚间，北大医药股份有限公司公告称，公司总办会经研究、评估北京北医医药有限公司（以下简称"北医医药"）的经营现状，认为北医医药近年来 的主营业务长期高度依赖于与北京大学国际医院的业务合作，在2025年5月与北京大学国际医院终止业务合作后，自2025年6月以来主营业务已基本中止，其 与北京大学国际医院的业务合作事项进入交接收尾阶段。 由于北医医药截至目前始终未能寻找到同类型业务，因此可能面临主营业务全面终止、人员分 流、企业转型的风险。(格隆汇) ...

消息面上，北大医药发布公告称，近日，公司总办会经研究、评估子公司北京北医医药有限公司(以下 简称"北医医药")的经营现状，认为子公司北医医药近年来的主营业务长期高度依赖于与国际医院的业 务合作，在5月与国际医院终止业务合作后，自6月以来主营业务已基本中止，其与国际医院的业务合作 事项进入交接收尾阶段。由于北医医药截止目前始终未能寻找到同类型业务，因此可能面临主营业务全 面中止、人员分流、企业转型的风险。上述事项预计将导致公司自6月起至2025年年末可能面临销售收 入减少约6亿元，净利润减少约4000万元的风险。公司生产经营可能面临较大压力，北医医药也正面临 可能关停并转的困难局面。 北京商报讯(记者丁宁)8月12日，北大医药（000788）盘中跌逾6%，截至北京商报记者发稿，报6.48元/ 股，跌幅为6.49%。 ...

Background Overview - The company, Peking University Medicine Co., Ltd., has a long-term service contract with Peking University International Hospital for the supply and distribution of medical equipment, surgical instruments, drugs (excluding special drugs), in vitro diagnostic reagents, and medical consumables, which was approved in April and May 2022. The contract is valid for three years [1]. Progress Update - The company received notification in November 2024 that the long-term service contract with the International Hospital will end in May 2025, and a bidding process for the supply of in vitro diagnostic reagents and medical consumables will be initiated, inviting the company to participate [2]. - Following the termination of the business cooperation in May 2025, the company's subsidiary, North Medical Medicine, will face a complete halt in its main business operations starting June 2025, as it has not found similar business opportunities. This situation may lead to significant operational challenges, including personnel restructuring and potential business transformation [3]. Financial Impact - The company anticipates a revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit reduction of about 40 million yuan (28.99% of the latest audited net profit attributable to shareholders) from June 2025 to the end of that year. Furthermore, from 2026 onwards, the expected revenue decline could reach about 1.027 billion yuan (49.85% of the latest audited revenue) and a net profit decrease of approximately 68.69 million yuan (49.78% of the latest audited net profit attributable to shareholders) [3].

Group 1 - Beijing Beida Pharmaceutical's subsidiary, Beijing Beida Medicine, has suspended its main business since June 2025 due to the termination of a long-term service contract with Peking University International Hospital [1] - The termination reflects the subsidiary's weak business structure and inability to diversify its client base, which may lead to operational sustainability issues and potential personnel adjustments [1] - The parent company may experience short-term performance impacts as a result of this development [1] Group 2 - Huaxi Biological's fermentation-derived chondroitin sodium has successfully completed the main document registration with the National Medical Products Administration, marking it as the first compliant fermentation-derived chondroitin sodium in China [2] - This new pharmaceutical-grade raw material can be applied in Class II and III medical devices, potentially expanding the company's raw material business applications and serving as a new growth point for performance [2] - Future market expansion and downstream customer integration will be critical for the commercial success of this product [2] Group 3 - Tongrentang announced a change in leadership, with the resignation of Chairman Di Shubing and the election of Zhang Zhaohua as the new chairman [3] - This leadership change is part of normal internal rotation and may indicate a strategic management strengthening and business development push for the company [3] Group 4 - *ST Wuzhong has initiated arbitration against Regen Biotech, Inc. for breach of contract, with the Shenzhen International Arbitration Court accepting the case [4] - The arbitration seeks to confirm the validity of the exclusive agency agreement and may involve a preliminary claim for damages amounting to RMB 1.6 billion, covering various losses [4] - The outcome of this arbitration could significantly impact *ST Wuzhong's operational pressure and stock price, depending on the ruling [4] Group 5 - Rongchang Bio's RC148 has been proposed for inclusion in the breakthrough therapy designation program for treating advanced or metastatic non-small cell lung cancer [5] - This PD-1/VEGF dual antibody is the fourth of its kind to receive such designation, following competitors like Kangfang Biotech and Promis [5] - The competitive landscape for multi-target dual antibodies is intensifying, and Rongchang's progress may further drive technological advancements in the industry [5]

Core Viewpoint - The company faces significant risks due to its heavy reliance on a major client, Beijing University International Hospital, with the termination of their business cooperation expected to lead to substantial revenue and profit declines starting in mid-2025 [2][4][5]. Business Dependency - Beijing Beiyi Pharmaceutical Co., Ltd. has been the sole provider of procurement, logistics, and distribution services for medical equipment, surgical instruments, and consumables to the International Hospital, with a contract set to expire in May 2025 [3][4]. - The company has not identified alternative business opportunities, which raises concerns about a complete halt in operations and potential layoffs [4][5]. Financial Impact - The anticipated financial impact includes a revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit reduction of about 40 million yuan (28.99% of the latest audited net profit) from June 2025 to the end of that year [2][4]. - From 2026 onwards, the company may face a revenue drop of around 1.027 billion yuan (49.85% of the latest audited revenue) and a net profit decline of approximately 68.69 million yuan (49.78% of the latest audited net profit) [2][4]. Transition Efforts - The company is actively exploring new directions for the transformation of Beiyi Pharmaceutical to mitigate the impact of the business termination, although the success of this transition remains uncertain [5]. - If the company fails to find a viable transformation path, it may face further operational challenges and potential shutdown [5]. Historical Context - The company has undergone several name changes and has a history of significant financial fluctuations, with net profits reported at 55.61 million yuan in 2022, 44.36 million yuan in 2023, and 137.99 million yuan in 2024 [6][8]. - As of March 31, 2025, the company reported a total revenue of approximately 502.36 million yuan, with a slight growth rate of 1.70% [8].